Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI3032 single ascending dose in healthy volunteers
NCT07134127Phase 1Completed
- Sponsor
- Innovent Biologics
- Start
- Aug 2025
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of IBI3032 (10 cohorts), sponsored by Innovent Biologics. Primary endpoints: Serious Adverse Events at 15 days and Adverse Events at 15 days. Started Aug 2025; status: completed.
02
Drugs
IBI3032
Beyond the preview
Go deeper on NCT07134127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07134127.